This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why Clorox (CLX) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
How to Boost Your Portfolio with Top Consumer Staples Stocks Set to Beat Earnings
by Zacks Equity Research
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
5 Well-Placed Stocks in a Prospering Soap & Cleaning Materials Industry
by Rajani Lohia
Pricing initiatives, innovation, digital transformation and brand building are crucial to the success of companies in the soap and cleaning materials industry, especially amid rising costs. Companies like PG, CL, HENKY, CHD, and CLX are well-positioned to thrive through these efforts.
Clorox's (CLX) Pricing & Cost Saving on Track: Apt to Hold?
by Zacks Equity Research
Clorox (CLX) benefits from robust pricing and cost-saving initiatives. The company's IGNITE strategy also bodes well.
Will Clorox (CLX) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Clorox (CLX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Why Investors Need to Take Advantage of These 2 Consumer Staples Stocks Now
by Zacks Equity Research
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Conagra Brands (CAG) Q4 Earnings Coming Up: Factors to Note
by Zacks Equity Research
Conagra Brands' (CAG) fourth-quarter performance is likely to reflect lower volumes due to an industry-wide slowdown in consumption.
Helen of Troy (HELE) Q1 Earnings Coming Up: Factors to Note
by Zacks Equity Research
Helen of Troy's (HELE) first-quarter performance is likely to reflect the adverse impact of pressured consumer spending. Persistent inflationary headwinds are a concern.
Can Constellation Brands (STZ) Beat Q1 Earnings Amid High Costs?
by Zacks Equity Research
Constellation Brands' (STZ) Q1 results are likely to reflect gains from a strong beer portfolio, growth in Power Brands and premiumization. Inflationary costs are expected to have weighed on margins.
McCormick (MKC) Q2 Earnings Coming Up: Factors to Note
by Zacks Equity Research
McCormick's (MKC) second-quarter performance is likely to reflect the adverse impact of lower volumes and inflationary headwinds. Also, rising SG&A costs are a concern.
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why Investors Need to Take Advantage of These 2 Consumer Staples Stocks Now
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Will General Mills (GIS) Top Estimates in Q4 Earnings Release?
by Zacks Equity Research
General Mills' (GIS) Q4 results are likely to reflect gains from the Accelerate strategy amid soft Pet unit sales and cost inflation.
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Here's Why Clorox's (CLX) Strategic Efforts Appear Good
by Zacks Equity Research
Clorox (CLX) benefits from robust pricing and cost-saving initiatives. The company's IGNITE strategy also bodes well.
Why Is Clorox (CLX) Down 8.2% Since Last Earnings Report?
by Zacks Equity Research
Clorox (CLX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Clorox (CLX) Benefits From Strategic Actions Amid High Costs
by Zacks Equity Research
Clorox (CLX) is poised for significant expansion by focusing on the implementation of its pricing strategy and cost saving initiatives amid cost-related hurdles.
Here's Why Clorox (CLX) is a Strong Growth Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why Clorox (CLX) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Clorox (CLX) Q3 Earnings Beat Estimates, Revenues Down Y/Y
by Zacks Equity Research
Clorox's (CLX) third-quarter fiscal 2024 bottom line benefits from pricing actions and cost-saving initiatives. The company also boasts a solid innovation pipeline.
Clorox (CLX) Reports Q3 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
While the top- and bottom-line numbers for Clorox (CLX) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Here's How Clorox (CLX) is Placed Ahead of Q3 Earnings Release
by Zacks Equity Research
Clorox (CLX) third-quarter results are likely to reflect challenges related to continued impacts of the recent cyberattack incident, inflationary costs and elevated SG&A expense.
Why Clorox (CLX) Might Surprise This Earnings Season
by Zacks Equity Research
Clorox (CLX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
What Analyst Projections for Key Metrics Reveal About Clorox (CLX) Q3 Earnings
by Zacks Equity Research
Besides Wall Street's top -and-bottom-line estimates for Clorox (CLX), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2024.